Efficacy and safety of various acetylsalicylic acid formulations

Cover Page

Cite item

Full Text

Abstract

The review article discusses the efficacy and safety of 3 different acetylsalicylic acid (ASA) formulations: a simple (uncoated, non-enteric coated), enteric coated and buffered formulations. We discussed in detail the results of several domestic clinical studies concerning the direct comparison of enteric coated and buffered formulations of ASA. It was shown that the dosage form of the drug can affect both the efficiency and safety of the treatment. In particular, we have shown the data that the buffered formulation has more significant antiplatelet effect and in a lesser degree damages the mucous membrane of the gastrointestinal tract in comparison with enteric coated ASA formulations.

About the authors

N. M Vorobyeva

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: natalyavorobjeva@mail.ru
ст. науч. сотр. лаб. сердечно-сосудистого старения обособленного структурного подразделения ГБОУ ВПО РНИМУ им. Н.И.Пирогова «Российский геронтологический научно- клинический центр» 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Панченко Е.П., Добровольский А.. Тромбозы в кардиологии. Механизмы развития и возможности терапии. М.: Спорт и культура, 1999.
  2. Patrono C, Coller B, Fitz-Gerald G.A.et al. Platelet-Active Drugs: The Relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy 2004. Chest 2004; 126: 234s-264s.
  3. Eikelboom J.W, Hirsh J, Spencer F.A et al. Antiplatelet Drugs. Antithrombotic therapy and prevention of thrombosis, 9th ACCP Evidence - based Clinical Practice Guidelines. Chest 2012; 141 (2): 89s-119s.
  4. Antithrombotic Trialists’ Collaboration. Collaborative meta - analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
  5. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-6.
  6. Taylor D.W, Barnett H.J.M, Haynes R.B et al. Low - dose and high - dose acetylsalicylic acid for patients undergoing carotid endarterectomy: randomised controlled trial. Lancet 1999; 353: 2179-83.
  7. Mangano D.T. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309-17.
  8. Pearson T.A, Blair S.N, Daniels S.R et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patient without Coronary or other Atherosclerotic Vascular Diseases. Circulation 2002; 106: 388-91.
  9. Насонов Е.Л., Каратеев А.Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов. Клин. медицина. 2000; 78 (3): 4-10.
  10. Brooks P.M, Day R.O. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991; 324 (24): 1716-25.
  11. Wallace J.L, Mc Knight G.W. The mucoid cap over superficial gastric damage in the rat. A high - pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 1990; 99 (2): 295-304.
  12. Somasundaram S, Hayllar H, Rafi S et al. The biochemical basis of non - steroidal anti - inflammatory drug - induced damage to the gastrointestinal tract: a review and hypothesis. Scand J Gastroenterol 1995; 30 (4): 289-99.
  13. Sagar K.A, Smyth M.R. A comparative bioavailability study of different aspirin formulations using on - line multidimensional chromatography. J Pharm Biomed Anal 1999; 21: 383-92.
  14. Cox D, Maree A.O, Dooley M et al. Effect of enteric coating on antiplatelet activity of low - dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-8.
  15. Pedersen A, Fitz-Gerald G. Dose - related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.
  16. Endo H, Hosono K, Inamori M et al. Incidence of small bowel injury induced by low - dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 2009; 79: 44-51.
  17. Endo H, Sakaib E, Higurashib T. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44: 833-8.
  18. Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric - coated aspirin. Scand J Gastroenterol 2011; 46: 803-9.
  19. Баркаган З.С., Котовщикова Е.Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клин. фармакология и терапия. 2004; 13 (3): 1-4.
  20. Верткин А.Л., Аристархова О.Ю., Адонина Е.В. и др. Безопасность и фармакоэкономическая эффективность применения различных препаратов ацетилсалициловой кислоты у пациентов с ИБС. Рус. мед. журн. 2009; 17 (9): 570-5.
  21. Яковенко Э.П., Краснолобова Л.П., Яковенко А.В. и др. Влияние препаратов ацетилсалициловой кислоты на морфофункциональное состояние слизистой оболочки желудка у кардиологических пациентов пожилого возраста. Сердце. 2013; 12 (3): 145-50.
  22. Ломакин Н.В., Русанова А.В., Бурячковская Л.И., Вершинина М.Г. Сравнение антиагрегантной эффективности разных форм ацетилсалициловой кислоты. Сердце. 2014; 78 (4): 206-14.
  23. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric - coated and buffered low - dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181-91.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).